[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Queen's Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":204},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,68,90,116,140,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100556996","implementing-a-contingency-management-program-addressing-methamphetamine-use-for-and-with-the-people-of-hawaii-100556996",false,"NCT06532370","Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii","Inclusion Criteria:\n\n* Admitted trauma patients\n* Age greater than 18 years old\n* Urine drug screen positive for methamphetamines during the current hospitalization\n* Report at least weekly methamphetamine use\n* First methamphetamine use greater than 6 months prior to injury\n* Report at least 4 DSM-V Amphetamine-Type Substance Use Disorder symptoms (at least moderate disease)\n* Glasgow Coma Scale ≥13 upon arrival to the emergency department\n* Ability to understand and participate in study procedures\n* Ability to communicate in English\n\nExclusion Criteria:\n\n* Active psychosis (reporting auditory or visual hallucinations)\n* Under ongoing cardiorespiratory monitoring\n* Evidence of moderate or severe traumatic brain injury\n* Patients who are known to be pregnant\n* Prisoner\n* Individuals incarcerated at the time of their hospitalization\n* Individuals lacking capacity to provide, or are otherwise unable or unwilling to provide written informed consent","ALL","18 Years",{"count":18,"type":19},40,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this clinical trial is to use contingency management (CM) as an intervention tool to address methamphetamine use.\n\nThe main objectives are to:\n\n* Gather effectiveness data on a pilot a CM program for participants in Hawaii who use methamphetamine following hospitalization due to traumatic injury\n* To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program.\n\nParticipants will:\n\n* Visit a follow-up clinic up to three times per week to complete urinalysis following discharge from the trauma unit\n* Complete Treatment Effectiveness Assessments at 6 and 12-weeks\n* Engage in a qualitative interview at the end of the CM program",[25,26],"Contingency Managment","Methamphetamine Use Disorder","RECRUITING","2026-03-29",{"date":30,"type":31},"2026-03-31","ACTUAL",{"date":33,"type":31},"2024-10-10",{"date":35,"type":19},"2026-12-30",{"name":37,"class":38},"Queen's Medical Center","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":39},"100620540","feasibility-and-acceptability-of-point-of-care-rapid-syphilis-testing-among-patients-seeking-family-planning-services-in-hawaii-100620540","NCT07358949","Feasibility and Acceptability of Point of Care Rapid Syphilis Testing Among Patients Seeking Family Planning Services in Hawai'i","Inclusion Criteria:\n\n* 14 years or older\n* Seeking contraception or abortion services\n* Sexually active (engages in any form of sexual activity with another person)\n* Denies history of syphilis infection\n* Can speak and read English\n* Displays capacity for informed consent\n\nExclusion Criteria:\n\n* Confirmed history (by patient report or medical records) of syphilis\n* Home address outside Hawai'i\n* Currently incarcerated\n\nNumber of Subjects:\n\nRecommendations for sample size in pilot studies range from 70 to 100 patients.28 Given this is a nonrandomized feasibility study with no comparator (i.e., to a control or to serological testing), we aim to enroll 50 to 75 participants to support analysis for correlation between variables while being able to achieve relatively small confidence intervals. This number takes into account the practical considerations of study personnel resources and in-person patient volume in our clinic. All patients eligible for the rapid syphilis testing will be approached for study participation.",true,"FEMALE","14 Years",{"count":50,"type":19},70,"OBSERVATIONAL","The purpose of the study is to see if rapid syphilis testing at the time of a family planning (contraception or abortion) visit is acceptable and practical for patients.\n\nThis study involves a fingerstick blood sample for syphilis testing during a family planning visit. Results will be ready in 10-15 minutes.\n\nPotential Benefits\n\n* Participants can find out whether they are syphilis positive or negative within the visit, as soon as 10-15 minutes of the finger stick. Typically, syphilis testing results take several days.\n* If positive, there is the option of starting treatment within the same day.\n\nPotential Risks\n\n* The study team will do everything possible to protect participants' privacy, including removing names and other identifiable information from study materials, however this is still a small chance there may be a breach of privacy during the study.\n* Physical risks of fingerstick are exceptionally rare when sterile technique is used. The study team will be using all best practices to reduce risk of infection or injury.\n* There is a risk of discomfort or pain with fingerstick collection. The risk of scarring is usually only associated with repeat draws, for example in patients with diabetes who have to do fingerstick draws multiple times per day.\n* There is a very small chance that the positive result is incorrect (also known as a \"false positive\"), meaning the participant does not actually have syphilis. To confirm the result, the investigators recommend that any positive rapid syphilis result be followed up with a blood test at the lab.\n\nCost for Participation\n\no There is no direct cost to participate in this study. After consent is signed, the participant received renumeration of $50 in form of gift card. If the participant tests positive for a syphilis infection, the participant or their health insurance will be responsible cover the costs of this medical treatment. If they do not have access to health insurance, the study team will connect the participant with agencies that have assisted patients with treatment at a reduced cost or free of cost.",[54],"Syphilis Infection",[56,57,58],"feasibility","rapid syphilis testing","family planning","NOT_YET_RECRUITING","2026-03-16",{"date":62,"type":31},"2026-03-19",{"date":64,"type":19},"2026-03-30",{"date":66,"type":19},"2027-12",{"name":37,"class":38},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":46,"sex":47,"minAge":16,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":20,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":89,"locationsCount":39},"100497174","early-phase-1-exploring-the-effects-of-an-intravaginal-lactic-acid-gel-on-the-vaginal-microbiome-100497174","NCT05753813","Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome","Inclusion Criteria:\n\n* Age 18-54\n* Female\n* Pre-menopausal\n* Can speak and read in English\n* Displays capacity for informed consent\n* Has had 2 or more documented and\u002For self-reported episodes of symptomatic BV or candida infection in the last year, requiring, over-the-counter or prescription treatment\n\nExclusion Criteria:\n\n* Pregnant or trying to become pregnant\n* Post-menopausal\n* Using NuvaRing device\n* A past medical history of kidney disease, recurrent UTI, and\u002For urinary tract abnormalities\n* Current UTI\n* Using Phexxi as a contraceptive during the collection period of the study","54 Years",{"count":76,"type":19},22,[78],"EARLY_PHASE1","This project aims to investigate if the contraceptive method, Phexxi, causes changes to the composition of the vaginal microbiome. The investigators hypothesize that regular use of Phexxi will cause increased colonization of lactic acid-producing lactobacilli, which could have positive effects in the way of preventing recurrent episodes of BV and candida infections.",[81,82],"Bacterial Vaginosis","Vulvovaginal Candidiasis","2026-02-18",{"date":85,"type":31},"2026-02-20",{"date":87,"type":31},"2023-12-15",{"date":35,"type":19},{"name":37,"class":38},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":20,"phases":98,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},"100587822","vapocoolant-spray-to-reduce-pain-with-nexplanon-insertion-100587822","NCT06933381","Vapocoolant Spray to Reduce Pain With Nexplanon Insertion","Topical Vapocoolant to Reduce Pain With Nexplanon Insertion: A Randomized Controlled Trial","Inclusion Criteria:\n\n* At least 14 years or older\n* Undergoing an etonogestrel implant insertion in the arm in POB1 Suite 1004 or POB2 Suite 402\n* English speaking\n* Able and willing to sign the informed consent form and agree to terms of the study\n\nExclusion Criteria:\n\n* Required or requested narcotics, anxiolytics, IV sedation, or general anesthesia for the procedure\n* Known previous exposure to vapocoolant spray\n* Nexplanon removal and reinsertion same day during visit in the same arm\n* Contraindications to vapocoolant spray components (ethyl chloride and 1,1,1,3,3-pentafluoropropane\u002F1,1,1,2-tetrafluroethane)\n* Unable to provide written, informed consent in English",{"count":50,"type":19},[22],"The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.",[101],"Reducing Pain With Nexplanon Implant Insertion",[103,104,105,106],"Vapocoolant spray","Pain with Nexplanon insertion","Contraceptive implant insertion","Vapocoolant","2026-01-07",{"date":109,"type":31},"2026-01-09",{"date":111,"type":31},"2025-06-16",{"date":113,"type":19},"2026-05-01",{"name":37,"class":38},3,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":20,"phases":124,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":39},"100587654","why-wait-initiating-contingency-management-in-traumatically-injured-patients-during-hospitalization-100587654","NCT06931197","Why Wait? Initiating Contingency Management in Traumatically Injured Patients During Hospitalization","Inclusion Criteria:\n\n* Admitted trauma patients\n* Age greater than 18 years old\n* Urine drug screen positive for methamphetamines during the current hospitalization\n* Report at least weekly methamphetamine use\n* First methamphetamine use greater than 6 months prior to injury\n* Report at least 4 Diagnostic and Statistical Manual of Mental Disorders 5th Edition, Amphetamine-Type Substance Use Disorder symptoms (at least moderate disease)\n* Glasgow Coma Scale ≥13 upon arrival to the emergency department\n* Ability to understand and participate in study procedures\n* Ability to communicate in English\n* Expected discharge date within 45 days on the day of screening \u002F recruitment\n\nExclusion Criteria:\n\n* Active psychosis (reporting auditory or visual hallucinations)\n* Under ongoing cardiorespiratory monitoring\n* Evidence of moderate or severe traumatic brain injury\n* Patients who are known to be pregnant\n* Prisoners\n* Individuals incarcerated at the time of their hospitalization\n* Individuals lacking capacity to provide, or are otherwise unable or unwilling to provide written informed consent",{"count":123,"type":19},20,[22],"This clinical trial is to implement contingency management (CM) as an intervention tool to address methamphetamine use and will be initiated during inpatient acute hospitalization in trauma injured patients.\n\nThe goals are:\n\n* Gather effectiveness data on a CM program for participants in Hawaii who use methamphetamine during hospitalization and following discharge due to trauma injury\n* To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program.\n* To assess the rate of leaving against medical advice (AMA) and treatment completion in acute hospital setting in participants.\n* To assess the optimal timing of CM initiation for traumatically injured hospitalized patients by comparing patient outcomes (i.e. duration of CM participation and rates of CM program completion and providing negative urine samples) to NCT06532370 where CM was initiated after discharge from the hospital.\n\nFor total of 12 weeks, participants will:\n\n* Be visited on Mondays\u002FThursdays or Tuesdays\u002FFridays by the research team to complete urine analysis during the hospitalization\n* Visit a follow up clinic up to 2 times per week on Mondays\u002FThursdays or Tuesdays\u002FFridays to complete urinalysis following discharge from the hospital\n* Complete Treatment Effectiveness Assessments at 6 and 12 weeks\n* Engage in qualitative interview at the end of the CM program",[127,26],"Contingency Management",[129,26,130,131],"Contingency management","Contingency management during acute hospitalization","Contingency management in Trauma Injured Patients","2025-12-09",{"date":134,"type":31},"2025-12-17",{"date":136,"type":19},"2026-01-01",{"date":138,"type":19},"2026-07-31",{"name":37,"class":38},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":20,"phases":150,"briefSummary":151,"conditions":152,"keywords":157,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":39},"100589209","assessing-acceptability-and-feasibiity-of-sti-self-swab-testing-to-be-offered-at-the-time-of-telemed-medication-abortion-provision-100589209","NCT06951438","Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision","STI Self-swab Testing At the Time of Telemed Medication Abortion Provision","STAMP","Inclusion Criteria:\n\n1. Patients of the Queen Medical Center Options Center clinic seeking telemedicine medication abortion.\n2. Patients for whom, according to the CDC guidelines for STI Testing11, STI testing is indicated, or patients who desire STI screening\n3. Age 14 and over\n4. Can speak and read English\n5. Displays capacity for informed consent\n\nExclusion Criteria:\n\n1. Home address that is not located in the state of Hawai'i\n2. Incarcerated\n3. Unwilling to perform vaginal swab collection",{"count":149,"type":19},75,[22],"The goal of this interventional study is to provide more access to STI testing for patients who seek abortion care through telemedicine, particularly for those whose access to STI testing is otherwise limited. The main questions it aims to answer are:\n\nWhat is the acceptability, feasibility, and utilization of self-collected STI screening at the time of telemedicine medication abortion provision?\n\nHow does the uptake of such a service among patients receiving telemedicine abortion care compare to the population of patients who seek in-person medication abortion care?\n\nWhat are the positivity rates for STIs in among patients receiving telemedicine medication abortion care compared to the positivity rates for a contemporaneous, in-clinic population?\n\nWhat is the average time to between testing and treatment for patients who test positive for an STI using the self-collection service?\n\nResearchers will compare the intervention group to a contemporaneous, in-clinic population on uptake of STI screening, as well as on positivity rates for the STIs tested.\n\nParticipants will be asked to perform self-swab collection for STI testing for gonorrhea, chlamydia, and trichomonas. They will be instructed to send their specimens to a lab using prepaid postage. Upon completion of sample collection and shipping, they will be asked to complete a survey assessing basic demographic information, as well as acceptability and feasibility of the intervention. Patients who test positive for an STI will be promptly provided\u002Freferred to treatment.",[153,154,155,156],"Sexually Transmitted Disease (STD)","Gonorrhea","Chlamydia","Trichomonas Infection",[158,159,160,161,162],"STI testing","telemedicine","medication abortion","self-swab collection","vaginal swab","2025-06-25",{"date":165,"type":31},"2025-06-26",{"date":167,"type":31},"2025-05-22",{"date":169,"type":19},"2026-06-30",{"name":37,"class":38},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":20,"phases":181,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":39},"100436606","phase-2-evaluation-of-treatment-predictors-reflecting-beta-catenin-activation-in-hepatocellular-carcinoma-100436606","NCT04965454","Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma","Clinical Trial of Biomarkers for Predicting Immunotherapy Response in Hepatocellular Carcinoma","ExTRACT-HCC","Inclusion Criteria:\n\n* Age 18 years or older (no upper limit of age)\n* Hepatocellular carcinoma diagnosis made histologically or radiographically in accordance to National Comprehensive Cancer Network guidelines (3.2019 version or higher)\n* Does not qualify for surgical resection or locoregional therapy alone or has disease that has progressed after surgical resection and\u002For locoregional therapy\n* Has measurable disease defined as at least one tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 on CT\u002FMRI completed within past 6 weeks of eligibility screening\n* Under the care of a licensed medical oncologist\n* Life expectancy \\> 6 months\n* Deemed eligible for treatment with an immune checkpoint inhibitor agent based on the treating medical oncologist's assessment of previous treatment failure, clinical\u002Fperformance\u002Fvirology status, and liver\u002Frenal\u002Fhematologic function.\n* Child-Pugh score of 9 or less\n* Creatinine clearance ≥ 40 mL\u002Fmin, measured or calculated using the Cockcroft-Gault formula\n* ALT and AST ≤7x upper limit of normal\n* Total bilirubin ≤4 mg\u002FdL\n* Albumin ≥2.8 g\u002FdL\n\nExclusion Criteria:\n\n* Weight \\> 500 lbs (PET\u002FCT limit)\n* Pregnant or lactating female (those of child-bearing potential must be re-screened within 7 days prior to PET\u002FCT imaging)\n* Serious underlying medical condition that would impair patient's ability to tolerate the imaging procedure\n* Concurrent treatment with a non-targeted therapeutic agent. Concurrent enrollment in an ICI-treatment trial and combination ICI treatment are allowed.",{"count":180,"type":19},80,[182],"PHASE2","This prospective clinical trial will evaluate PET\u002FCT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable hepatocellular carcinoma (HCC). The primary objective of this diagnostic trial is to assess the accuracy of pre-treatment fluorine-18 (18F-) fluorocholine (FCH) PET\u002FCT for predicting a lack of objective response (LOR) after 16 weeks of ICI therapy.",[185],"Hepatocellular Carcinoma Non-resectable",[187,188,189,190,191,192,193,194,195],"hepatocellular carcinoma","immunotherapy","positron emission tomography","mutation profiling","liquid biopsy","personalized medicine","diagnostic","fluorocholine","immune checkpoint inhibitor","2025-04-28",{"date":198,"type":31},"2025-05-01",{"date":200,"type":31},"2022-03-28",{"date":202,"type":19},"2028-06-30",{"name":37,"class":38},""]